Press coverage about Recro Pharma (NASDAQ:REPH) has trended somewhat positive recently, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Recro Pharma earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 47.5527060871257 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several brokerages have recently commented on REPH. Zacks Investment Research lowered shares of Recro Pharma from a “buy” rating to a “hold” rating in a report on Thursday, November 16th. Piper Jaffray Companies restated a “buy” rating and issued a $11.00 price objective on shares of Recro Pharma in a report on Friday, October 27th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $11.65.

Recro Pharma (NASDAQ:REPH) traded up $0.21 during trading on Thursday, reaching $9.78. 91,500 shares of the company’s stock were exchanged, compared to its average volume of 120,743. Recro Pharma has a 12 month low of $5.81 and a 12 month high of $10.59. The company has a current ratio of 1.59, a quick ratio of 1.35 and a debt-to-equity ratio of 0.50.

In other Recro Pharma news, major shareholder Healthcare Master Fun Broadfin sold 100,000 shares of the stock in a transaction that occurred on Tuesday, December 5th. The shares were sold at an average price of $10.00, for a total transaction of $1,000,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 644,813 shares of company stock worth $6,191,579. 21.60% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Recro Pharma (REPH) Earning Somewhat Positive News Coverage, Analysis Shows” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/12/14/recro-pharma-reph-earning-somewhat-positive-news-coverage-analysis-shows.html.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.